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Background. Nephrotic syndrome is associated with hyper-
cholesterolemia, hypertriglyceridemia, and marked elevations
of plasma low-density lipoprotein (LDL) and very low-density
lipoprotein (VLDL). Hypertriglyceridemia in nephrotic syn-
drome is accompanied by increased hepatic fatty acid synthe-
sis, elevated triglyceride secretion, as well as lipoprotein lipase,
VLDL-receptor, and hepatic triglyceride lipase deficiencies,
which lead to impaired clearance of triglyceride-rich lipopro-
teins. Acyl CoA: diacylglycerol acyltransferase (DGAT) is a
microsomal enzyme that joins acyl CoA to 1, 2-diacylglycerol to
form triglyceride. Two distinct DGATs (DGAT-1 and DGAT2)
have recently been identified in the liver and other tissues. The
present study tested the hypothesis that the reported increase
in hepatic triglyceride secretion in nephrotic syndrome may be
caused by up-regulation of DGAT.
Methods. Male Sprague-Dawley rats were rendered nephro-
tic by two sequential injections of puromycin aminonucleoside
(130 mg/kg on day 1 and 60 mg/kg on day 14) and studied on
day 30. Placebo-treated rats served as controls. Hepatic DGAT-
1 and DGAT-2 mRNA abundance and enzymatic activity were
measured.
Results. The nephrotic group exhibited heavy proteinuria, hy-
poalbuminemia, hypercholesterolemia, hypertriglyceridemia,
and marked elevation of VLDL concentration. Hepatic DGAT-
1 mRNA, DGAT-1, and total DGAT activity were significantly
increased, whereas DGAT-2 mRNA abundance and activity
were unchanged in the nephrotic rats compared to the con-
trol animals. The functional significance of elevation of DGAT
activity was illustrated by the reduction in microsomal free fatty
acid concentration in the liver of nephrotic animals.
Conclusion. Nephrotic syndrome results in up-regulation of
hepatic DGAT-1 expression and activity, which can potentially
contribute to the associated hypertriglyceridemia by enhanc-
ing triglyceride synthesis. Thus, it appears that both depressed
catabolism and increased synthetic capacity contribute to hy-
pertriglyceridemia of nephrotic syndrome.
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Plasma concentrations of triglycerides, very low-
density lipoprotein (VLDL), and intermediate-density
lipoprotein (IDL) are increased, and triglyceride content
of various lipoproteins is elevated in humans and ani-
mals with nephrotic syndrome [1–6]. This is accompanied
by impaired clearance of VLDL, chylomicrons, and their
remnants in nephrotic syndrome [1, 6–11]. The latter is
caused by down-regulations of lipoprotein lipase [12, 13],
hepatic triglyceride lipase [14], and VLDL receptor [15],
which are the primary pathways of plasma triglyceride-
rich lipoprotein clearance. These findings point to the role
of impaired catabolism of triglyceride-rich lipoproteins
in the pathogenesis of hypertriglyceridemia in nephrotic
syndrome. In addition, increased hepatic production of
fatty acids and triglycerides has been demonstrated in
various models of nephrotic syndrome [16–19]. Increased
hepatic production of fatty acids in rats with nephrotic
syndrome has been shown to be caused by elevated en-
zymatic activity of acyl-CoA carboxylase and fatty acid
synthase, the key enzymes in fatty acid biosynthesis.
However, because of the lack of appropriate molecu-
lar tools, the precise mechanism of increased hepatic
triglyceride synthesis in nephrotic syndrome has not been
investigated.
Acyl CoA: diacylglycerol acyltransferase (DGAT) is
an endoplasmic reticulum membrane–associated enzyme
that catalyzes the final step in biosynthesis of triglycerides
by covalently joining a long chain fatty acylCoA to dia-
cylglycerol [20]. DGAT plays a critical role in a number
of major physiologic functions, such as intestinal lipid ab-
sorption, packaging of lipoproteins, storage of fat in adi-
pose tissue and muscle, milk and egg production, which
all depend on triglyceride synthesis. Although existence
of DGAT activity has been known for many years [21],
and the enzyme had been partially purified [22, 23], un-
til recently the genes encoding DGAT were not identi-
fied. Cases et al [24] were the first to identify the mouse
cDNA for a DGAT that was subsequently termed DGAT-
1. Cells infected with the virus harboring DGAT-1 gene
were shown to produce a 498 amino acid, 47-kD pro-
tein with exclusive substrate specificity for diacylglycerol
262
Vaziri et al: DGAT expression in nephrosis 263
and acyl-CoA. The enzyme is expressed in all human and
mouse tissues. Although DGAT-1 is most abundant in the
small intestine [24], it is not entirely essential for intesti-
nal absorption of triglycerides or production of chylomi-
crons because these processes are not severely impaired
in DGAT-1–deficient mice [25]. DGAT-1 is a member
of the ACAT-DGAT gene family. It has 20% sequence
homology with ACAT, which uses sterol as opposed to
diglycerol as the acyl acceptor. Interestingly, while ex-
hibiting reduced body fat, resistance to diet-induced obe-
sity and lactation defect, DGAT-1 knockout mice have
normal plasma triglycerides concentration and abundant
adipocyte triglyceride content [26]. These observations
led to identification of DGAT-2, which bears no sequence
homology with DGAT-1 and, unlike the latter, its activ-
ity is inhibitable by high concentration (100 mmol/L) of
MgCl2. DGAT-2 is abundantly expressed in the liver and
white fat, but unlike DGAT-1, is minimally expressed in
the small intestine [27]. Based on its cDNA sequence,
DGAT-2 is expected to encode a 388 amino acid pro-
tein with an approximate molecular mass of 44.5 kD [27].
Relative preservation of intestinal absorption in DGAT-1
knockout mice is, in part, caused by a compensatory up-
regulation of DGAT-2 and diglycerol acyltransferase [27].
To our knowledge, the effect of nephrotic syndrome
on DGAT gene expression and activity has not been pre-
viously investigated. We therefore sought to investigate
gene expressions and activities of DGAT-1 and DGAT-2
in the liver of rats with experimental nephrotic syndrome.
Liver was chosen for this study because it is the source of
endogenous triglycerides in the circulation.
METHODS
Animal study groups
Male Sprague-Dawley rats weighing 180 to 200 g were
housed in temperature- and light-controlled space with
12-hour light (500 lux) and 12-hour dark (≤5 lux) cy-
cles. The rats were allowed free access to food (Purina
Rat Chow, Purina Mills, Inc., Brentwood, MO, USA) and
water. Animals were randomized into the nephrotic and
normal control groups. The rats assigned to the nephrotic
group received sequential intraperitoneal injections of
puromycin animonucleoside on day 1 (130 mg/kg) and
day 14 (60 mg/kg). The rats assigned to the control group
received placebo injections of 5% dextrose in water.
Thirty days after the initial puromucin or placebo injec-
tions, animals (N = 6 per group) were placed in individual
metabolic cages for a 24-hour urine collection. The next
day, under general anesthesia (Nembutal 50 mg/kg, IP),
the animals were sacrificed between the hours of 9 and
11 a.m., and the liver was immediately removed, frozen
in liquid nitrogen, and stored at −70◦C for subsequent
processing. In addition, blood was collected using car-
diac puncture. Plasma lipids, lipoproteins, albumin, and
urinary creatinine and protein concentrations were mea-
sured by a method described in our earlier study [28].
Hepatic microsomal free fatty acid concentrations were
measured using the NEFA C kit purchased from Wako
Chemicals (Richmond, VA, USA).
Preparation of liver microsomes
Hepatic microsomes were isolated as described previ-
ously [29]. Briefly, 500 mg of frozen liver were homoge-
nized in 6 mL of ice-cold buffer A containing 50 mmol/L
Tris/HCl, pH 7.4, 250 mmol/L sucrose, 1 mmol/L EDTA,
and protease inhibitors (1 mmol/L PMSF, 10 lg/mL apro-
tinin, 5 lg/mL leupeptin, and 3 lg/mL pepstatin). The tis-
sue homogenate was centrifuged at 1200g for 15 minutes
at 4◦C. The supernatant was collected and centrifuged at
9000g for 15 minutes at 4◦C. Microsomes in the second
supernatant were then precipitated by centrifugation at
100,000g for 45 minutes at 4◦C. The final pellet consist-
ing of microsomal membrane was resuspended in 600 lL
of buffer A, divided into aliquots, and stored at −70◦C
until used. Protein concentration was measured using a
protein assay kit (Bio-Rad, Hercules, CA, USA).
DGAT-1 and DGAT-2 activity assays
The DGAT activity in the microsomal fraction was
measured as described by Coleman [30]. The as-
say is based on DGAT-catalyzed production of [14C]
trioleoylglycerol from [1-14C] oleoyl-CoA and 1,2-
dioleoylglycerol. Because DGAT-2 activity is inhibitable
by high concentrations of Mg, DGAT-1 activity was as-
sessed as DGAT activity in the presence of 100 mmol/L
MgCl2 [27]. In brief, the reaction mixture used for to-
tal DGAT activity contained 175 mmol/L Tris-HCl (pH
8.0), 8 mmol/L MgCl2, 5 mg/mL fatty acid-free BSA,
200 lmol/L 1,2-dioleoylglycerol, 30 lL of [1-14C] oleoyl-
CoA (50 lCi/mL, 56 mCi/mmol) and 50 lg of microsomal
protein in 200 lL total volume. In parallel experiments,
a medium containing 100 mmol/L MgCl2 was used to
inhibit DGAT-2 activity. The reaction was initiated by
addition of [1-14C] oleoyl-CoA, and incubation of mix-
ture for 30 minutes at 25◦C. The reaction was terminated
by adding 1.5 mL of a solution containing 2-propanol-
heptane-water (80:20:2, v/v). The mixture was then vor-
texed briefly, 1 mL heptane and 0.5 mL water were added
and gently vortexed again and centrifuged at 1000g for
10 minutes. Therefore, 1 mL of the top heptane phase
was transferred to a new reaction tube, to which 2 mL
of alkaline ethanol solution (ethanol:0.5 N NaOH: water,
50:10:40, v/v) were added. The contents were then thor-
oughly mixed and centrifuged at 1000g for 10 minutes. A
650-lL aliquot of the top heptane phase containing [14C]
trioleoylglycerol was transferred to a scintillation vial to
which 5 mL of Bio-Safe II scintillation fluid were added
and radioactivity measured using a Liquid Scintillator
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Table 1. Primers and probes used for real time RT-PCR
GeneBank
Gene DNA sequence accession no.
Fa 5′-CAGACCAGCGTGGGCG-3′
DGAT-1 Rb 5′-GAACAAAGAGTCTTGCAGACGATG-3′ NM 053437
Pc 5′-6-FAM-CGGCCACTGGGAGCTGAGGTG-3′
F 5′-GGAACCGCAAAGGCTTTGTA-3′
DGAT-2 R 5′-AATAGGTGGGAACCAGATCAGC-3′ AJ487787
P 5′-6-FAM-AGCTGGCCCTGCGCCATGG-3′
F 5′-ACATCCAAGGAAGGCAGCAG-3′
18s rRNA R 5′-TCGTCACTACCTCCCCGG-3′ X01117
P 5′-VIC-CGCGCAAATTACCCACTCCCGA-3′
aForward primer; breverse primer; cprobe.
(Beckman Coulter, Inc., Fulterton, CA, USA). DGAT-1
and DGAT-2 activities were determined from measure-
ments of total DGAT activity and the DGAT activity
obtained in the presence of 100 mmol/L MgCl2.
RNA preparation and real time RT-PCR
Total RNA was isolated from frozen liver using TRI-
zol reagent (Invitrogen, Carlsbad, CA, USA) and purified
by RNeasy kit (Qiagen, Valencia, CA, USA) according
to the manufacturer’s procedures. RNA concentration
was determined by spectrophotometry. Quantitative real
time RT-PCR was performed with ABI 7700 real time
PCR thermocycler using a kit obtained from Applied
Biosystems (Foster City, CA, USA). RNA (0.2 lg) was
converted to cDNA by reverse transcription in a mix-
ture of 5.5 mmol/L MgCl2, 0.5 mmol/L of each dNTPs,
2.5 lmol/L of random hexamer, 0.4 unit of RNase in-
hibitor, and 1.25 units of reverse transcriptase in 5-lL
volume. The reaction mixture was incubated for reverse
transcription for 10 minutes at room temperature before
undergoing one cycle of 10 minutes at 25◦C, 30 minutes
at 48◦C, and 5 minutes at 95◦C.
PCR was performed using AmpliTaq DNA polymerase
in a 25 lL mixture containing 5.5 mmol/L of MgCl2,
0.2 mmol/L of each dATP, dCTP, and dGTP, 0.4 mmol/L
of dUTP, 0.25 units of AmpliTaq DNA polymerase, 5 lL
of reverse transcription mixture, and 0.2 lmol/L of 5′- and
3′-primers and 0.1 lmol/L of 6-FAM–conjugated probe
specific for DGAT-1 or DGAT-2 gene. VIC-conjugated
probe and primers specific for 18s rRNA were used as
internal control. The primer sequences employed in the
study are summarized in Table 1. PCR amplification was
carried out for 45 cycles consisting of denaturation at
94◦C for 15 seconds, and annealing/extension at 60◦C for
1 minute. The amplification process was analyzed and vi-
sualized using the Applied Biosystems Sequence Detec-
tor software. The cycle number in the logarithmic phase
(Ct value) was used to assess relative mRNA abundance
in hepatic tissue from control and nephrotic rats. Mean
normalized expression of DGAT-1 and DGAT-2 genes
were calculated using 18s rRNA expression as a refer-
ence [31].
Table 2. Urinary protein excretion, creatinine clearance, plasma
albumin, creatinine, total cholesterol (chol), free chol, LDL chol,
VLDL chol, triglyceride, and free fatty acids (FFA) concentrations in
the nephrotic and control groups
CTL NS P value
Total cholesterol mg/dL 59 ± 2.2 264 ± 16.7 ≤0.001
Free cholesterol mg/dL 16.9 ± 2.0 70.7 ± 8.1 ≤0.001
LDL mg/dL 26.6 ± 2.7 173 ± 15.6 ≤0.001
VLDL mg/dL 9.3 ± 0.9 33.4 ± 2.9 ≤0.001
Total/HDL chol ratio 2.7 ± 0.3 4.8 ± 0.5 ≤0.001
Triglycerides mg/dL 46.7 ± 4.5 175 ± 16.7 ≤0.001
FFA mEq/L 0.62 ± 0.04 1.1 ± 0.06 ≤0.001
Plasma albumin mg/dL 3.8 ± 0.1 2.3 ± 0.2 ≤0.001
Plasma creatinine mg/dL 0.38 ± 0.01 0.43 ± 0.03 NS
Ccr mL/min 2.65 ± 0.2 2.43 ± 0.1 NS
Urine protein mg/24h 10 ± 1.3 217 ± 25 ≤0.001
Body weight g 372 ± 8.3 318 ± 5 <0.001
Six animals were included in each group.
Data analysis
Student t test and regression analysis were used in
statistical analysis of the data, which are presented as
mean ± SEM. P values equal to or less than 0.05 were
considered significant.
RESULTS
General data
Data are summarized in Table 2. As expected, the
nephrotic group exhibited heavy proteinuria, hypoalbu-
minemia, and unchanged creatinine clearance. This was
accompanied by significant hypercholesterolemia, hyper-
triglyceridemia, and marked elevations of plasma VLDL
and LDL concentrations and increased total cholesterol-
to-HDL-cholesterol concentration ratio. In contrast, liver
microsomal free fatty acid concentration was significantly
reduced in the nephrotic animals when compared with
that in the control group.
DGAT data
Data are depicted in Figures 1–4. Total DGAT enzy-
matic activity was significantly increased in the nephrotic
rats as compared to that found in the control group. This
was accompanied by and primarily caused by elevated
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Fig. 1. Hepatic microsomal total DGAT activity and free fatty acid
concentration in the nephrotic (NS) and normal control (CTL) groups.
DGAT activity is presented as nmol of trioleoylglycerol/mg protein/
hour. N = 6 in each group, ∗P < 0.05.
DGAT-1 activity. Elevation of the liver DGAT-1 enzy-
matic activity was accompanied by a parallel increase
in DGAT-1 mRNA abundance. In contrast, liver tissue
DGAT-2 mRNA abundance and DGAT-2 enzymatic ac-
tivity were unchanged in the nephrotic animals.
Microsomal free fatty acid concentration inversely cor-
related with DGAT activity (r = −0.67, P < 0.001).
DISCUSSION
Nephrotic syndrome results in profound alteration of
lipid metabolism and plasma lipid profile. Recent dis-
coveries of genes encoding several major lipid regula-
tory enzymes and receptors have helped to decipher the
molecular basis of many aspects of nephrotic dyslipi-
demia. For instance, expression of hepatic HMG-CoA
reductase is up-regulated, whereas LDL receptor abun-
dance is reduced, and cholesterol 7a-hydroxylase (rate-
limiting step in cholesterol conversion to bile acid) is
unchanged in nephrotic syndrome [32–35]. These find-
ings can account for hypercholesterolemia, elevated level
and impaired clearance of LDL in nephrotic syndrome.
In addition, hepatic HDL receptor (SRB-1) and plasma
lecithin: cholesterol acyltransferase (LCAT) levels are
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Fig. 2. Mean normalized DGAT-1 gene expression and DGAT-1 ac-
tivity in the liver of nephrotic (NS) and normal control (CTL) groups.
18s rRNA was used as reference for DGAT-1 gene expression. N = 6
in each group, ∗P < 0.05.
severely reduced in nephrotic syndrome [36, 37]. These
abnormalities can account for impaired maturation and
depressed clearance of HDL cholesterol in nephrotic syn-
drome. Finally, hepatic expression of Acyl CoA: choles-
terol acyltransferase-2 (ACAT-2) is markedly elevated
in nephrotic animals [38]. Together these findings have
helped to discern the underlying mechanisms involved
in the pathogenesis of altered cholesterol metabolism
in nephrotic syndrome. In addition, and as noted in the
introduction, down-regulation of lipoprotein lipase and
VLDL receptor in skeletal muscle and adipose tissues
and of hepatic triglyceride lipase [16, 17, 18, 21, 22] have
unraveled the underlying mechanisms responsible for im-
paired clearance of triglyceride-rich lipoproteins (VLDL
and chylomicrons) and their remnants in nephrotic
syndrome.
Recent identification of genes for DGAT, which cat-
alyzes the final step in triglyceride production [16, 24, 26,
27], has provided the opportunity to explore regulation of
triglyceride biosynthesis in a variety of relevant physio-
logic and pathologic conditions, including dyslipidemias,
obesity, and other metabolic disorders. The present study
sought to examine the expression and activity of hepatic
tissue DGAT in nephrotic syndrome, which is a prototype
of acquired hyperlipidemia. The liver was chosen because
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Fig. 3. Mean normalized DGAT-2 gene expression and DGAT-2 ac-
tivity in the liver of nephrotic (NS) and normal control (CTL) groups.
18s rRNA was used as reference for DGAT-2 gene expression. N = 6
in each group.
it is the source of VLDL, which is the primary vehicle for
the transport of endogenous triglycerides to the sites of
consumption (myocytes) and storage (adipocytes).
The nephrotic animals exhibited a significant up-
regulation of DGAT-1 gene expression, DGAT-1 activ-
ity, and total DGAT enzymatic activity in the liver tissue.
This was accompanied by a significant reduction of hep-
atic microsomal free fatty acid concentration that pro-
vides functional evidence for the increased hepatic tissue
DGAT activity. This supposition was further supported
by the inverse correlation between liver tissue microso-
mal DGAT activity and free fatty acid concentration.
Interestingly, hepatic DGAT-2 mRNA abundance and
activity were unchanged. This observation suggests that
nephrotic syndrome exclusively affects the expression of
hepatic DGAT-1, which is closely related to ACAT, whose
expression and activity are also elevated in the nephrotic
liver [38]. Up-regulation of hepatic DGAT-1 expression
and activity shown here reveals the molecular mechanism
of increased hepatic triglyceride biosynthesis and secre-
tion shown in previous studies [18, 19]. The precise mech-
anism responsible for up-regulation of DGAT-1 expres-
sion and activity in the nephrotic liver is unclear. DGAT
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Fig. 4. Correlations between hepatic microsomal free fatty acid con-
centration and DGAT activity in the nephrotic (◦) and normal control
(•) groups.
activity is stimulated by fatty acids in cultured hepato-
cytes [39–41]. Accordingly, increased fatty acid synthesis,
occasioned by elevation of acetyl-CoA carboxylase and
fatty acid synthase, in the nephrotic liver shown by Joles
et al [16, 17] can, at least in part, account for the ob-
served up-regulation of DGAT-1 activity and expression
in nephrotic syndrome.
Elevation of the liver tissue DGAT activity points to
enhanced triglyceride synthetic capacity in the nephrotic
liver. Thus, both increased hepatic synthesis and dimin-
ished peripheral clearance of triglycerides are involved
in the pathogenesis of nephrotic hypertriglyceridemia.
The authors wish to point out that the elevations of
hepatic DGAT-1 and total DGAT activities were rela-
tively mild. This raises the question as to whether the ob-
served up-regulation of hepatic triglyceride biosynthetic
capacity can play a significant role in the pathogenesis
of nephrotic hypertriglyceridemia. The authors believe
that the answer to this question is definitely affirma-
tive. This is because in the face of depressed triglyceride
catabolism, minimally elevated (even unchanged) triglyc-
eride biosynthetic capacity is inappropriate and sufficient
to generate and maintain marked hypertriglyceridemia in
the steady-state chronic phase. Moreover, the true magni-
tude of up-regulation of hepatic DGAT-1 expression and
activity are underestimated by traditional expression of
data per units of RNA and protein mass, respectively.
This is because nephrotic syndrome in this rat model is
associated with an approximate 20% to 25% increases in
size, total protein, and RNA contents of the liver, despite
modest reduction in body weight [32].
CONCLUSION
Nephrotic syndrome results in up-regulation of hepatic
DGAT-1 expression and activity, which can potentially
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contribute to the pathogenesis of the nephrotic hy-
pertriglyceridemia by augmenting hepatic triglyceride
production.
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